Nasdaq
$250.69▼ 0.12%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $37.01BShares out 1.500M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
8- 10.5After-hours26.10.06 06:004Ownership#●●●
BIOGEN INC.
Sean Godbout, an executive at Biogen Inc., has filed a Limited Power of Attorney appointing Michael Parini, Wendell Taylor, and Bryan Keighery as attorneys-in-fact to fulfill reporting obligations under Section 16 of the Securities Exchange Act. This administrative filing authorizes the designated representatives to prepare and submit required SEC filings, such as Forms 3, 4, and 5, on his behalf.…more
$250.69-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 8.12After-hours26.08.13 05:503Ownership
BIOGEN INC.
On August 11, 2026, Michael Parini of Biogen Inc. filed a Limited Power of Attorney appointing Wendell Taylor and Bryan Keighery as his attorneys-in-fact. This authorization grants the designated individuals the authority to prepare and file Section 16 reports, including Forms 3, 4, and 5, with the SEC on his behalf.…more
$250.69-0.12%vs prev closeView filingShare - 8.6Regular26.08.06 23:17SCHEDULE 13G/AOwnership
BIOGEN INC.
FMR LLC와 그 계열사들이 2026년 6월 30일 기준 바이오젠(Biogen Inc.)의 보통주에 대해 5% 이상의 지분을 보유하고 있음을 공시했습니다. 이번 보고는 FMR LLC 및 애비게일 P. 존슨을 포함한 주요 주주들의 지분 현황과 의결권 행사 구조를 명시하고 있습니다.…more
$250.69-0.12%vs prev closeView filingShare
7 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 6d agoPre-market26.10.19 20:30#●●●#●●●
Biogen to Present New Nephrology Portfolio Data at ASN Kidney Week
Biogen will present long-term Phase 3 data for EMPAVELI and research updates for its investigational candidate felzartamab at the ASN Kidney Week. These presentations focus on reinforcing existing clinical efficacy and highlighting progress in the company's nephrology pipeline.…more
$250.69-0.12%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 10.5Regular26.10.06 02:35
●●●●●●●● ●●●●● ●●●●●●
Large-scale options transactions have been detected in several major healthcare stocks. These whale alerts provide traders with insights into potential market shifts and unusual trading patterns.…more
$250.69-0.12%vs prev closeShareBenzinga - 10.5Pre-market26.10.05 20:10
●●●●●●●● ●●●●● ●●●●●●
Stoke Therapeutics announced that the FDA is willing to accept its planned Phase 3 cognition and behavior analysis for Zorevunersen in Dravet syndrome. This agreement provides a clearer regulatory path for the company's clinical development program.…more
$250.69-0.12%vs prev closeShareBenzinga
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report